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Introduction
Breast Cancer (BC) is the second most common cancer among 
women. Research shows that many women with BC experi-
ence major depression and generalized anxiety disorder.2 Sig-
nificantly higher incidences of post-traumatic stress disorder 
and higher scores on emotional distress were also observed 
in women with breast cancer.3 One well-studied biological 
mechanism leading to anxiety, depression, and stress (ADS) 
is cytokine-induced behavioral changes in sick individuals.4 
There are both clinical and experimental evidence indicat-
ing that activation of the brain cytokine system is related to 
depression.4 Cytokine activation not only relates to depression 
but also to cancer development.4 Lyon et al have shown that 
many groups of cytokines were elevated in women with BC.5
Another biological change (other than cytokine activa-
tion) that has recently emerged as a potential mechanism for the 
development of depression is epigenetics.1 DNA methylation 
can prevent enzymes from binding to the promoter region of a 
gene and thereby cause up- or down-regulation of DNA tran-
scription,1 with these effects potentially being present for sites 
throughout the genome. An alternative means for altering the 
expression of genes is through position effects for genes local-
ized near the telomere (the ends of the chromosomes).6,7 As 
telomeres shorten, the reduction of heterochromatin could 
result in alterations in chromatin conformation, which leads 
to changes in the expression of nearby genes.8,9 Further-
more, shortening of telomeres is associated with increased 
levels of chromosomal instability, which, in turn, could lead 
to alterations in gene expression. It has been shown that 
accelerated telomere shortening is associated with psychosocial 
stress,10 and that hypermethylation is associated with panic 
disorder.11 Although there are growing numbers of research 
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studies indicating that epigenetic changes are associated with 
ADS, there is currently no evidence that this association is 
present in women with BC.
The goal of this study is to identify methylation patterns 
that are associated with three psychoneurological symptoms, 
ADS,  in women with BC.  A commonly used and well-validated 
questionnaire to measure anxiety and depression is the Hos-
pital Anxiety and Depression Scale (HADS),12 and a widely 
used and well-validated instrument for measuring perceived 
stress is the Perceived Stress Scale (PSS).13 Genome-wide 
methylation was assessed using the high-throughput Illumina 
Human Methylation 450K assay.
Traditionally, univariate models have been used to 
examine the relationship between molecular features and 
each outcome variable (ADS); nevertheless, analyzing mul-
tiple outcome variables globally has become more frequent in 
many fields of biomedical research.14 In fact, this approach 
is especially helpful for evaluating traits that appear related. 
For example, evidence that stress is related to depression 
and anxiety in women with BC comes from the results of 
a study by Varni et al, who found that higher levels of per-
ceived stress were associated with increased depression and 
anxiety among survivors of childhood cancer.15 Therefore, 
instead of fitting separate univariate models to each psy-
choneurological symptom, ADS can be treated as a cluster 
of related symptoms and included together in a multivariate 
linear model. Hence, an overarching goal of this study is 
to compare and contrast univariate and multivariate models 
when identifying molecular features associated with ADS 
in women with BC.
Methods
study design. The study included 73 women with BC 
in stage I (n = 21), II (n = 44), or III (n = 8). This research 
was approved by the Institutional Review Board at Virginia 
Commonwealth University (VCU IRB #HM 13194) and 
complied with the principles of the Declaration of Helsinki. 
The molecular features and ADS were measured at study 
enrollment, prior to their receiving chemotherapy. The sever-
ity of depression and anxiety was measured using the HADS, 
which is a 14-item questionnaire.12 Among the 14 items, 7 
assess anxiety and 7 assess depression. Each item is on a four-
level ordinal scale, the scale response is calculated such that 
the ordinal levels contribute 0–3 points, and the 14 items 
within each scale are summed. Using these sums, subjects 
may be classified as normal (score ,8), borderline (8–10), or 
having clinical anxiety or depression (score .10).16 Although 
the scale has an ordered structure, we used the continuous 
version of HADS in order to maintain all the information in 
the scale and protect power.
Stress was evaluated using a 10-item PSS.17 PSS was 
designed to measure the degree to which situations in one’s life 
are appraised as stressful.13 Items were designed to monitor how 
unpredictable, uncontrollable, and overloaded a respondent’s 
life is by asking about the respondent’s feelings and thoughts 
during the last month.17 Of the 10 total responses on the 
PSS, 6 were negative responses and were given the following 
numerical value: never = 0; almost never = 1; sometimes = 2; 
fairly often = 3; and very often = 4. The remaining four positive 
items in the PSS were scored in a reversed format according 
to standard approaches (ie, never = 4; …; very often = 0).18,19 
The scores were summed, with the higher total scores of PSS 
indicating higher overall stress.17
The Illumina Human Methylation 450K assay was used 
to profile human DNA methylation using whole blood from 
women diagnosed with breast cancer. The β-values were 
defined as the proportion methylated, and were reported for 
each CpG site using the minfi Bioconductor package20 in the 
R programing environment.21 β-values were plotted against 
the percentage of GC content across all samples. Based on the 
results, CpG sites with GC content greater than 40% were 
filtered out. CpG sites with all β-values over 0.9 or below 0.1 
were considered to be constitutively methylated or unmethy-
lated and therefore were excluded from the study.22 Because 
single nucleotide polymorphisms (SNPs) may affect the per-
formance of this assay,23 the CpG sites containing SNPs were 
also excluded. After filtering, 285,173 CpG sites remained. 
The Illumina Human Methylation 450K Assay uses two types 
of probe designs: Infinium I and Infinium II. Peak correction 
was used to align the M-values produced by the two types 
of probe designs (M-value = log(β/(l – β)).24 In this study, 
five subjects had multiple methylation profiles: because these 
profiles were highly correlated, the mean methylation levels 
were used. After taking the average, the M-values were back-
transformed into β-values, which were used in the analysis.
statistical analysis. The HADS and PSS scales were first 
examined using descriptive statistics. To identify the molecu-
lar features significantly associated with each of the scales, 
a linear regression model was fit to each of the 285,173 CpG 
sites. ADS were treated as three separate continuous responses. 
The P-values obtained from the linear regression models were 
adjusted using the Benjamini–Hochberg (BH) method to con-
trol the false discovery rate (FDR). CpG sites with an FDR 
less than 0.02 were considered to be significant.
The ADS values were plotted against each other to 
produce a scatterplot matrix. Pearson’s correlation among 
the three scales was also calculated. Based on the results, it 
seemed reasonable to fit a multivariate linear mixed model by 
combining all scales. The mixed model included a methyla-
tion component, two dummy coded indicators representing 
the type of psychoneurological symptom with anxiety as ref-
erent level, and the interactions between each indicator and 
the methylation component. In addition, the model included 
a subject-specific term to account for the correlation among 
scales. To illustrate the model with a formula, let Yij represent 
the HADS-Anxiety, HADS-Depression, and PSS outcome 
for ith subject, where j = l, 2, or 3, respectively. The model can 
then be expressed as
Molecular features associated with psychoneurological symptoms
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  1 1 2 2 3 3 4 4 5 5ij i i i i i i ijY x x x x x bα β β β β β= + + + + + + + 
where xi1 and xi2 are indicators representing depression and 
stress, xi3 is a methylation component, xi4 is the interaction 
between depression and the methylation component, and xi5 
is the interaction between stress and the methylation compo-
nent. The α and the β terms are the intercept and the slope 
coefficients, respectively, bi is the random subject effect, and 
ij is the sample error. The null hypothesis of no association 
between the methylation “signature” and ADS across differ-
ent psychological disorders was tested by the interaction effect. 
The likelihood ratio tests were used to compute P-values, 
and the resulting P-values were again adjusted using the BH 
method to control the FDR. In order to compare the perfor-
mance of the multivariate models versus the separate models, 
the FDR thresholds used in the multivariate mixed model was 
set at 0.02.
All statistical analyses were performed using the R program-
ming environment (version 3.0.2) and the lme4 package.21
results
The means and standard deviations for the three scales are 
provided in Table 1. The distributions of the three scales are 
shown in Figure 1. Although the distribution of HADS-
Depression is skewed somewhat to the right, based on the 
Central Limit Theorem, the mean of HADS-depression will 
follow a Gaussian distribution due to the large sample size 
(n = 73).25 Pearson’s correlation between anxiety and depres-
sion, anxiety and stress, and depression and stress were 0.657, 
0.668, and 0.715, respectively, indicating that the three out-
come scales were highly correlated; the scatterplot matrix sup-
ported this conclusion (Fig. 2).
When fitting separate models for each ADS scale, 
among 285,173 CpG sites, the sites with Illumina’s CpG 
loci ID (IlmnID) cg14474520, cg17527195, and cg23431989 
were significantly associated with depression (Table 2). Fur-
ther investigation suggested that the methylation level at 
sites cg14474520 and cg23431989 were positively associated 
with depression (slope coefficients: 104.6 and 70.52). How-
ever, at site cg17527195, the methylation level was negatively 
associated with depression (slope coefficient: –39.42). The 
scatter plots supported this conclusion (Fig. 3). The CpG 
site cg14474520 is located on gene FAM101A, and the CpG 
site cg23431989 is located on gene FOXJ1. Both FAM101A 
and FOXJ1 are cancer-related genes. It has been shown that 
down-regulation of FAM101A significantly reduces early 
Table 1. means and standard deviations of the three response 
variables.
ANxIETY DEPRESSIoN STRESS
mean 8.411 3.658 16.699
sD 3.523 3.220 8.100
Abbreviation: sD, standard deviation.
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Figure 1. Density plot of HaDs-anxiety, HaDs-Depression, and Pss.
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Figure 2. scatterplot matrix of HaDs-anxiety, HaDs-Depression, and Pss.
apoptosis in RKO colorectal cancer cells.26 Recent studies 
have suggested that FOXJ1 may be involved in the develop-
ment of more than one cancer. FOXJ1 can function as a tumor 
suppressor in breast cancer.27 It is also involved in adverse 
clinical outcome in ovarian cancers.28 Chen et al found that 
high expression of FOXJ1 is associated with prognosis and 
tumor cell proliferation in hepatocellular carcinoma.27 The 
CpG site cg17527195 cannot be mapped to any known genes 
at this time.
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After fitting multivariate models, the P-value histo-
grams support the notion that the multivariate model is more 
powerful in identifying significant CpG sites (Fig. 4). In 
Figure 4, the observed P-values for the CpG sites from the 
multivariate models are skewed more to the right compared 
to the three separate models (Fig. 4). The multivariate models 
identified 8,535 ADS-related CpG sites (FDR ,0.02). These 
8,535 significant CpG sites are located in different regions 
including 4,652 open sea (54.5%), 797 CpG islands (9.3%), 
622 north shelf (7.3%), 1,099 north shore (12.9%), 518 south 
shelf (6%), and 847 south shore (9.9%) sites. The CpG islands 
were defined as DNA sequences with greater than 50% GC 
bases and more than 60% CpG observed/expected ratio. 
The 2-kb sequences upstream and downstream of the CpG 
islands were defined as north and south shores, respectively, 
and the 2-kb sequences directly upstream and downstream of 
the shores were referred to as north or south shelves, respec-
tively. DNA methylation sites in regions other than these are 
annotated as “open sea”.23
Smaller numbers of significant sites can be identified 
by decreasing the FDR threshold (FDR = 0.01, number of 
significant sites = 6847; FDR = 0.005, number of significant 
sites = 4579; FDR = 0.001, number of significant sites = 8). 
The information for the eight significant CpG sites when 
FDR = 0.001 are shown in Table 3. Of particular interest 
among these eight significant sites is cg22749855, which 
is located within the SOCS3 gene and is associated with 
a gene promoter. SOCS3 is a well-studied oncogene, and 
hypermethylation of the SOCS3 promoter is an important 
regulatory mechanism for ulcerative colitis-related colorec-
tal cancer.29 Interestingly, ulcerative colitis-related colorectal 
cancer is a condition that has also been associated with telom-
ere shortening.30 Using the mouse as a model, researchers 
have found that the Socs3 gene is involved in depression in the 
mouse brain.31 SOCS3 has also been shown to play a role in 
limiting axon regeneration.32 Another interesting CpG site is 
cg11334709, which is located within the PIK3CD gene. The 
PIK3CD gene is associated with schizophrenia and increased 
expression of PIK3CD has been observed with a variation 
Table 2. Significant CpG sites from the separate models.
IlmnID gENE NAME LoCATIoN
anxiety
Depression cg14474520 family with sequence similarity 101, member a (FAM101A) 12:123346991
cg17527195 not associated with a gene 13:48301485
cg23431989 forkhead box J1 (FOXJ1) 17:71649364
stress
Note: Locations are defined as chromosome:coordinates and are based on NCBI Build 36.
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Figure 3. scatterplots of HaDs-Depression versus β-values for the three 
significant CpG sites.
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respectively). the bottom histogram represents the results from the 
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of ErB4, a critical neurodevelopmental gene.33 Figure 5 
demonstrates how methylation is differently associated with 
the three psychoneurological symptoms at these eight signifi-
cant CpG sites.
Additionally, we examined the robustness of our results 
by analyzing the modified version of HADS (HADS with 
items 7, 11, and 12 removed).16 The modified HADS was able 
to identify a larger number of significant CpG sites when fit-
ting mixed models using an FDR of 0.02 (10,856 sites). How-
ever, the univariate analyses using the modified HADS did 
not yield any significant CpG sites when the FDR was 0.02. 
These results are consistent with the unmodified HADS 
results, where we found 8,535 CpG sites significant when 
fitting mixed models but none that were significant univari-
ately for anxiety or PSS, and only three that were significant 
univariately for depression.
discussion
Although HADS is commonly used to measure anxiety 
and depression, many researchers have argued that HADS 
suffers from issues such as lack of consensus on an optimal 
cutpoint for detecting anxiety and depression, problematic fit 
of some items, and contradictory results regarding optimal 
dimensional structures.16 Lambert suggested that, instead of 
using the original 14 items, removing items 7, 11, and 12 can 
improve the model fit.16 Although in this current study the full 
HADS was analyzed to allow for comparisons of results with 
other published work, we also analyzed the modified HADS 
so that the results could be compared with the analysis of the 
original scale. For our methylation data, both the unmodi-
fied and modified HADS were able to identify a larger num-
ber of significant CpG sites when fitting mixed models using 
an FDR of 0.02 (8,535 and 10,856 CpG sites, respectively) 
in comparison with the univariate models. In fact, the uni-
variate analyses using the modified HADS did not yield any 
significant CpG sites for anxiety, depression, or perceived 
stress, which is similar to the unmodified HADS that only 
detected three CpG sites, all of which were significantly asso-
ciated with depression.
The sensitivity study conducted by Illumina stated that 
the Human Methylation 450 Assay is reliable when detecting 
Table 3. Annotation for eight significant CpG sites from the multivariate models using an FDR threshold of 0.001.
IlmnID gENE NAME (SYMBoL) RELATED ADS oR CANCERS LoCATIoN
cg11334709 PIK3CD antisense rna1 (PIK3CD-AS1)  
Phosphatidylinositol-4,5-bisphosphate  
3 kinase, catalytic subunit delta (PIK3CD)
Leukemia34
Colorectal cancer35
mantel cell lymphomas36
Hodgkin lymphomas37
Glioblastoma multiforme38
schizophrenia33
1:9638606
cg08885142 11:68973477
cg03128029 noP58 ribonucleoprotein (NOP58) 2:202851533
cg23043143 IQ motif containing e (IQCE) 7:2578627
cg11996860 8:102160991
cg06655216 12:88143460
cg22749855 suppressor of cytokine signaling 3 (SOCS3) Breast cancer39
Prostate cancer40
Pancreatic cancer41
Gastric cancer42
Colorectal cancer29
Depression (mouse model)31
17:73865547
cg16704590 ZnfX1 antisense rna 1 (ZFAS1)
small nucleolar rna, C/D box 12B (SNORD12B)
small nucleolar rna, C/D box 12 (SNORD12)
Breast cancer43 20:47330176
Notes: Locations are defined as chromosome:coordinates and are based on NCBI Build 36. Related ADS or cancers are the list of cancers or mental illness we 
found that are related to the particular gene where the significant CpG site is located.
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Figure 5. scatterplots of combined HaDs and Pss versus β-values for 
the eight significant CpG sites.
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a ∆β-value of at least 0.2.23 When comparing two groups, ∆β 
is the difference between the mean β-values in the two groups. 
Because our outcome was continuous, we defined ∆β as the 
range of β-values. Among three significant CpG sites found 
by separate models, only cg17527195 had a ∆β greater than 
0.2 (0.22); therefore, caution is needed when investigating the 
other two sites. Among 8,535 significant CpG sites found by 
the multivariate models using the unmodified HADS, 6,847 
had a ∆β greater than 0.2 (80%).
The results of our study demonstrate that the multivariate 
mixed model is more powerful than fitting separate models. 
Using multivariate models, a larger number of CpG sites were 
identified as significant. Figure 4 further demonstrated that 
the P-value distribution from the multivariate models was 
more skewed to the right compared to those from the univari-
ate models, giving rise to more significant findings at a fixed 
FDR. Therefore, when analyzing correlated psychoneurological 
symptom outcomes, multivariate models are recommended.
In the future, we will additionally have each patient’s 
cytokine levels assayed using the BioPlex system, telomere 
lengths using a fluorescent in situ hybridization (FISH)-based 
assay, and Illumina methylation levels at baseline and at sev-
eral follow-up time points. The multivariate mixed model 
approach will likewise be useful for analyzing longitudinally 
collected data.
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